Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Incyte Corporation
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Part 1: Eligible to receive any IEC therapy for any approved indication.
Part 2: Eligible to receive Yescarta for relapsed or refractory large B-cell lymphoma or follicular lymphoma.
Eastern Cooperative Oncology Group performance status 0 to 1.
Willingness to avoid pregnancy or fathering children
You may not be if
Evidence of active uncontrolled/untreated infection (viral, bacterial, fungal, opportunistic) of any origin.
Evidence of active hepatitis B virus or hepatitis C virus infection.
Known human immunodeficiency virus.
Active acute or chronic graft-versus-host disease requiring systemic therapy.
Concurrent use of chronic systemic steroids or immunosuppressant medications.
Any unresolved toxicity ≥ Grade 2 (except stable Grade 2 peripheral neuropathy or alopecia) from previous anticancer therapy.
Known history or prior diagnosis of immunologic or inflammatory/autoimmune disease affecting the central nervous system (CNS) and unrelated to their disease under study or previous treatment.
Clinically significant or uncontrolled cardiac disease.
Acute lymphoblastic leukemia participants with protocol-defined CNS status are eligible only in the absence of neurologic symptoms suggestive of CNS leukemia.
Diffuse large B-cell lymphoma participants must have no signs or symptoms of CNS disease or detectable evidence of CNS disease; participants who have been previously treated for CNS disease but have no evidence of disease at screening are eligible.
Laboratory values at screening outside the protocol-defined ranges.
